Meeting
2011 ASCO Annual Meeting
Overall survival effect of lower chemotherapy dosing in extremely obese (BMI ≥ 35) patients with breast cancer based on adjusted BSA.
Authors
P. Sharma
Georgia Health Sciences University, Augusta, GA
P. Sharma , T. A. Samuel , J. C. Wells , E. Mebel , J. T. French , J. A. Crozier , S. W. Looney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 29: 2011 (suppl; abstr 1047)
Abstract #
1047
Poster Bd #
15D
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A longitudinal assessment to evaluate the impact of higher body mass index on cancer-related fatigue in breast cancer patients receiving chemotherapy.
First Author: Julia Ellen Inglis
Poster
2016 ASCO Annual Meeting
Obesity as an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
First Author: Fatih Karatas
Poster
2016 Genitourinary Cancers Symposium
Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study.
First Author: Stefania Eufemia Lutrino
Poster
2013 ASCO Annual Meeting
Association of body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) who received targeted therapies (TT).
First Author: Gargi Surendra Patel